Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

4(66.7%)

Phase 4

2(33.3%)

6Total

N/A(4)

Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT00858676Phase 4Unknown

Impact of Acarbose on Abnormal Glucose Regulation in Patients With Coronary Artery Disease (AAA Trial)

Role: lead

NCT01548274Not ApplicableUnknown

Impact of Sarpogrelate in the Function of Endothelial Progenitor Cells

Role: lead

NCT00444717Phase 4Completed

Impact of Pitavastatin in Hypercholesterolemic Patients With Metabolic Syndrome

Role: lead

NCT01303042Not ApplicableUnknown

Efficacy of Insulin Lispro Mix 50/50 Therapy

Role: lead

NCT01303055Not ApplicableUnknown

Effects of Alogliptin on Pancreatic Beta Cell Function

Role: lead

NCT00553007Not ApplicableUnknown

The Relation Between Periodontal Disease and Metabolic Syndrome

Role: lead

NCT00262691Unknown

Investigation of Genetic Risk of Cardiovascular Disease in Prospective Cohort Study

Role: collaborator

All 7 trials loaded